Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134143) titled 'Safety Monitoring Study of Long-Term Iparomlimab and Tuvonralimab Administration in Solid Tumor Patients with Sustained Response' on Oct. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Foresea Life Insurance Guangzhou General Hospital
Condition:
Patients with cervical cancer or lung cancer confirmed by histological or cytological methods, as well as those diagnosed with liver cancer clinically
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-12
Target Sample Size: Experimental group:300;
Countries of Recruitment:
China
To know more, vis...